Background As vaccine roll-out continues across the globe as part of the efforts to protect
humanity against SARS-CoV-2, concerns are increasingly shifting to the duration of vaccine …

Background The duration and effectiveness of immunity from infection with and vaccination
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are relevant to …

Introduction To assess the incidence and risk factors for breakthrough COVID-19 infection in
a vaccinated cohort of patients with autoimmune rheumatic diseases (AIRDs) and determine …

We performed a review study according to recent COVID-19 vaccines' real-world data to
provide comparisons between COVID-19 vaccines regarding their relative efficacy. Although …

The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19
outcomes (hospitalization, critical care admission and death due to COVID-19) and its long …

Background Residents and staff in long-term care facilities have been prioritised for
vaccination against SARS-CoV-2, but data on potential waning of vaccine effectiveness and …

The lipid nanoparticle (LNP)-formulated mRNA vaccines BNT162b2 and mRNA-1273 are a
widely adopted multi vaccination public health strategy to manage the COVID-19 pandemic …

With the emergence of the SARS-CoV-2 Omicron variant in late 2021, Canadian public
health case/contact testing was scaled back due to high infection rates with milder symptoms …

Background: We evaluated the post-booster (BNT162b2) antibody responses in Singapore.
Methods: Participants (n= 43) were tested pre-booster and 20/30/60/90 days post-booster …

Several lines of evidence suggest that binding SARS-CoV-2 antibodies such as anti-SARS-
CoV-2 RBD IgG (anti-RBD) and neutralising antibodies (NA) are correlates of protection …